Les anti-TNF dans les maladies inflammatoires chroniques de l’intestin : peut-on mieux faire ? (notice n° 663458)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01796cam a2200265 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121193337.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Roblin, Xavier |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Les anti-TNF dans les maladies inflammatoires chroniques de l’intestin : peut-on mieux faire ? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 11 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | L’apparition des biosimilaires a permis d’avoir un impact médico-économique important pour nos systèmes de santé. Le concept de biobetter est a émergé, il y a peu, devant l’arrivée de biosimilaires permettant une amélioration clinique et/ou pharmacocinétique et/ou une acceptabilité plus favorable que la molécule princeps. L’infliximab sous-cutané (CT-P13 SC) remplit cette définition, en étant associé à une voie plus acceptable pour les patients et à une pharmacocinétique plus favorable. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Biosimilars have been associated with important cost savings in our healthcare system. The biobetter concept has emerged recently with the development of biosimilars demonstrating improvement of efficacy and/or pharmacokinetics and/or acceptability of the drug in comparison to the originator. Subcutaneous infliximab (CT-P13 SC) is associated with this new concept with a better acceptability due to the SC administration and more favorable pharmacokinetics. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | voie sous-cutanée |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | infliximab |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biobetter |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | CT-P13 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | infliximab |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biobetter |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | subcutaneous administration |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | CT-P13 |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 28 | 6 | 2021-06-01 | p. 763-769 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2021-6-page-763?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2021-6-page-763?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux